Hereditary Breast Cancer

¹ Center for Medical and Biotechnological Research of the University of Carabobo, Faculty of Health Sciences, University of Carabobo, Valencia, Venezuela

² Department of Physiological Sciences, School of Biomedical and Technological Sciences, Faculty of Health Sciences, University of Carabobo, Valencia, Venezuela

CP 2020, 2(1), 21–29;

Submitted: 20 November 2019 | Accepted: 24 February 2019 | Published: 18 March 2019

© 2019 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Breast cancer occurs when breast cells grow out of control because they escape the fine controls that regulate cell multiplication, resulting in cell proliferation unresponsive to regulation. Most cases of breast cancer have no identifiable cause, but approximately 5% to 10% are caused by inherited genetic mutations. Although other genes are known to cause hereditary breast cancer, most studies evaluating clinical management strategies have focused on women with mutations in the BRCA1 or BRCA2 (Breast Cancer) genes. People with these mutations have a significantly increased lifetime risk of cancer compared to the general population.

Keywords

Breast cancer

Hereditary mutations

BRCA1 gene

References

World Health Organization, 2012, Cancer. Fact Sheet. No. 297. Available from: http://www.who.int/mediacentre/factsheets/fs297/es/index.html. [Last accessed on 2012 March].

Jemal A, Bray F, Center MM, et al., 2011, Global Cancer Statistics. CA Cancer J Clin, 61:69–90.

Ministry of People’s Power for Health, Venezuela, 2010, Anuario de mortalidad 2010 [Mortality Yearbook 2010]. Available from: http://www.mpps.gob.ve/index.php?option=com_phoca download&view=category&id=11:anuarios-de- mortalidad. [Last accessed on 2013 January].

González L, Garavito A, Echeverri C, et al., 2007, Cáncer de mama: HER2/neu, métodos diagnósticos y consideraciones clínicas [HER2/neu and Breast Cancer: Diagnosis and Clinical Issues]. Rev Colomb Cancerol, 11:40–57.

Reigosa A, Fernández A, Gutiérrez D, et al., 2010, Expresión de p63 y citoqueratina 5/6 en los diferentes tipos moleculares del carcinoma de mama [p63 and Citokeratin 5/6 Expression in Different Molecular Subtypes of Breast Carcinoma]. Rev Esp Patol, 43:79–85.

Fernández A, Reigosa A, 2013, Clasificación molecular del cáncer de mama, obtenida a través de la técnica de hibridación in situ cromogénica (CISH) [Molecular Classification of Breast Cancer Patients Obtained through the Technique of Chromogenic in Situ Hybridization (CISH)]. Invest Clin, 54:406–6.

Rakha EA, Reis-Filho JS, Ellis IO, 2010, Combinatorial Expression of Biomarkers in Breast Cancer. Breast Cancer Res Treat, 120:293–308.

Narod SA, Rodríguez AA, 2011, Genetic Predisposition to Breast Cancer: BRCA1 and BRCA2 Genes. Public Health Mex, 53:420–9.

Apostolou P, Fostira F, 2013, Hereditary Breast Cancer: The Era of Novel Susceptibility Genes. Biomed Res Int, 2013:747318.

Lee EY, Muller WJ, 2010, Oncogenes and Tumor Suppressor Genes. Cold Spring Harb Perspect Biol, 2:1–18.

Perera RM, Bardeesy N, 2012, Oncogenes and Tumor Suppressor Genes in the Mammary Gland. Cold Spring Harb Perspect Biol, 4:34–66.

Silver DP, Livingston DM, 2012, Mechanisms of BRCA1 Tumor Suppression. Cancer Discov, 2:679–84.

Pal T, Vadaparampil ST, 2012, Genetic Risk Assessments in Individuals at High Risk for Hereditary Breast Cancer in the Breast Oncology Care Setting. Cancer Control, 19:255–66.

Meindl A, Ditsch N, Kast K, et al., 2011, Hereditary Breast and Ovarian Cancer: New Genes, New Treatments, New concepts. Dtsch Arztebl Int, 108:323–30.

Bertucci F, Finetti P, Birnbaum D, 2012, Basal Breast Cancer: A Complex and Deadly Molecular Subtype. Curr Mol Med, 12:96–110.

Peshkin BN, Alabek ML, Isaacs C, 2010, BRCA1/2 Mutations and Triple Negative Breast Cancers. Breast Dis, 32:25–33.

Trainer AH, Thompson E, James PA, 2011, BRCA and Beyond: A Genome-first Approach to Familial Breast Cancer Risk Assessment. Discov Med, 12:433–43.

Van der Groep P, Van der Wall E, Van Diest PJ, 2011, Pathology of Hereditary Breast Cancer. Cell Oncol (Dordr), 34:71–88.

Julian-Reynier C, 2011, Genetic Predisposition to Breast and Ovarian Cancer: Importance of Test Results. Med Sci (Paris), 27:657–61.

Pruthi S, Gostout BS, Lindor NM, 2010, Identification and Management of Women with BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc, 85:1111–20.

Milne RL, Antoniou AC, 2011, Genetic Modifiers of Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Ann Oncol, 22:11–17.

Smith KL, Isaacs C, 2011, BRCA Mutation Testing in Determining Breast Cancer Therapy. Cancer J, 17:492–9.

Gibert O, 2006, Estudio molecular de los genes BRCA1 y BRCA2 en cáncer de mama hereditario [Molecular Study of BRCA1 and BRCA2 Genes in Hereditary Breast Cancer]. Ed Cont Lab Clín, 9:19–27.

Karami F, Mehdipour P, 2013, A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer. Biomed Res Int, 2013:928562.

Birkbak NJ, Kochupurakkal B, Izarzugaza JM, et al., 2013, Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations. PLoS One, 8:80023.

Millot GA, Carvalho MA, Caputo SM, et al., 2012, A Guide for Functional Analysis of BRCA1 Variants of Uncertain Significance. Hum Mutat, 33:1526–37.

Rademakers SE, Rijken PF, Peeters WJ, et al., 2011, Parametric Mapping of Immunohistochemically Stained Tissue Sections; A Method to Quantify the Colocalization of Tumor Markers. Cell Oncol, 34:119–29.

Prasad K, Tiwari A, Ilanthodi S, et al., 2011, Automation of Immunohistochemical Evaluation in Breast Cancer Using Image Analysis. World J Clin Oncol, 2:187–94.

Paradiso A, Formenti S, 2011, Hereditary Breast Cancer: Clinical Features and Risk Reduction Strategies. Ann Oncol, 22:31–6.

Mackay J, Szecsei CM, 2010, Genetic Counselling for Hereditary Predisposition to Ovarian and Breast Cancer. Ann Oncol, 21:334–8.

George SH, Shaw P, 2014, BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol, 23:4–5.

Li D, Bi FF, Cao JM, et al., 2013, Effect of BRCA1 on Epidermal Growth Factor Receptor in Ovarian Cancer. J Exp Clin Cancer Res, 32:102.

Burco T, Cimponeriu D, Ion DA, et al., 2013, Analysis of Several BRCA1 and BRCA2 Mutations in A Hospital-based Series of Unselected Breast Cancer Cases. Chirurgia (Bucur), 108:468–72.

Mahdi KM, Nassiri MR, Nasiri K, 2013, Hereditary Genes and SNPs Associated with Breast Cancer. Asian Pac J Cancer Prev, 14:3403–9.

Berzina D, Nakazawa-Miklasevica M, Zestkova J, et al., 2013, BRCA1/2 Mutation Screening in High-risk Breast/Ovarian Cancer Families and Sporadic Cancer Patient Surveilling for Hidden High-risk Families. BMC Med Genet, 14:61.

Kang HJ, Hong YB, Yi YW, et al., 2013, Correlations Between BRCA1 Defect and Environmental Factors in the Risk of Breast Cancer. J Toxicol Sci, 38:355–61.

Guinan EM, Hussey J, McGarrigle SA, et al., 2013, A Prospective Investigation of Predictive and Modifiable Risk Factors for Breast Cancer in Unaffected BRCA1 and BRCA2 Gene Carriers. BMC Cancer, 13:138.

Mazzola E, Cheng SC, Parmigiani G, 2013, The Penetrance of Ductal Carcinoma in Situ among BRCA1 and BRCA2 Mutation Carriers. Breast Cancer Res Treat, 137:315–8.

Meyer P, Landgraf K, Högel B, et al., 2012, BRCA2 Mutations and Triple-negative Breast Cancer. PLoS One, 7:38361.

Larsen MJ, Thomassen M, Tan Q, et al., 2014, RNA Profiling Reveals Familial Aggregation of Molecular Subtypes in Non-BRCA1/2 Breast Cancer Families. BMC Med Genomics, 7:9.

Lara K, Consigliere N, Pérez J, et al., 2012, BRCA1 and BRCA2 Mutations in Breast Cancer Patients from Venezuela. Biol Res, 45:117–30.

Previous article in this issue

Next article in this issue

Cancer Plus, Electronic ISSN: 2661-3840 Print ISSN: 2661-3832, Published by AccScience Publishing